Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis
US6921809B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2000 |
| Grant date | Jul 26, 2005 |
| Priority date | — |
| Expiry date | Oct 12, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention related to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion by applying recombinant DNA technology to bacterial peptides. The present invention provides an effcient process for the expression in Escherichia coli of heterlogous proteins as fusion peptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations. What is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k of Neisseria meningitides B:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promoter of E. coli and of the terminator of the transcription of the phage T4, including restrictions sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.